BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Z, Liu Q. Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. J Gen Virol. 2018;99:44-61. [PMID: 29235977 DOI: 10.1099/jgv.0.000987] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Fasolato S, Pigozzo S, Pontisso P, Angeli P, Ruscica M, Savarino E, De Martin S, Lupo MG, Ferri N. PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. J Clin Med 2020;9:E3134. [PMID: 32998342 DOI: 10.3390/jcm9103134] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Reference Citation Analysis]
3 Li Z, Liu Q. Hepatitis C virus regulates proprotein convertase subtilisin/kexin type 9 promoter activity. Biochem Biophys Res Commun 2018;496:1229-35. [PMID: 29397939 DOI: 10.1016/j.bbrc.2018.01.176] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Grewal T, Buechler C. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond. IJMS 2022;23:1070. [DOI: 10.3390/ijms23031070] [Reference Citation Analysis]
5 Li Z, Liu Q. Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF-2. FEBS Lett 2018;592:2323-33. [PMID: 29885262 DOI: 10.1002/1873-3468.13152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
6 Li HC, Yang CH, Lo SY. Cellular factors involved in the hepatitis C virus life cycle. World J Gastroenterol 2021; 27(28): 4555-4581 [PMID: 34366623 DOI: 10.3748/wjg.v27.i28.4555] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Filippatos TD, Christopoulou EC, Elisaf MS. Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors? Curr Opin Lipidol 2018;29:333-9. [PMID: 29994840 DOI: 10.1097/MOL.0000000000000523] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 5.3] [Reference Citation Analysis]
8 Mahboobnia K, Pirro M, Marini E, Grignani F, Bezsonov EE, Jamialahmadi T, Sahebkar A. PCSK9 and cancer: Rethinking the link. Biomed Pharmacother 2021;140:111758. [PMID: 34058443 DOI: 10.1016/j.biopha.2021.111758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kandangwa M, Liu Q. HCV NS5A hyperphosphorylation is involved in viral translation modulation. Biochem Biophys Res Commun 2019;520:192-7. [PMID: 31585734 DOI: 10.1016/j.bbrc.2019.09.105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]